Moderna (#MRNA) Stock Forecast & Predictions for 2025, 2026, 2027–2030, 2040 and Beyond

Moderna (#MRNA) is a biotechnology company that has gained recognition for its innovative mRNA technology and its role in the development of a vaccine for the novel coronavirus disease (COVID-19). The success of mRNA technology has demonstrated the company’s potential in the fight against infectious diseases, paving the way for new therapeutic approaches.

This article reviews the company’s development trajectory, analyzes key factors affecting its share price, and presents a forecast for Moderna shares for 2025–2030 and beyond.

The article covers the following subjects:

Major Takeaways

• The current price of #MRNA is $30.98 as of 22.07.2025.
• The MRNA price reached its all-time high of $484.47 on 09.08.2021. The stock’s all-time low of $12.26 was recorded on 05.08.2019.
• Most analysts concur that MRNA shares will grow in the second half of 2025. According to several industry experts, the asset price is projected to rise to $37.93–$42.85 by the end of the year. At the same time, conservative forecasts suggest a decline to $31.12.
• Analysts and experts are optimistic about the Moderna stock in 2026. Some analytical agencies project an increase in MRNA shares to $45.91. According to more optimistic forecasts, the price could surge to $70.59. However, according to CoinCodex, the value of Moderna may plunge to $28.82 by year-end.
• Several global analytical agencies are bullish about the MRNA market, offering optimistic projections for 2027–2030. According to their estimates, the value of Moderna shares may rise to $82.68. The most optimistic forecasts project an increase to $316.30. Conversely, pessimistic forecasts indicate a decline in the MRNA value to $16.32.
• Long-term forecasts for MRNA shares from 2040 to 2050 also show significant variation. Some analysts project that the price of the trading instrument will reach $1,474.00 by 2050. Other analysts have set a more modest price target of $115.68.

MRNA Real-Time Market Status

The #MRNA stock is trading at $30.98 as of 22.07.2025.

When analyzing the Moderna stock, it is essential to monitor key indicators such as market capitalization, price movement, the number of shares outstanding, and the P/E ratio. These indicators help assess the company’s scale, attractiveness to investors, and MRNA‘s rate changes over the long term.

Indicator	Value
Market cap	$12.50 billion
All-time high	$484.47
All-time low	$12.26
Shares outstanding	386.74 million
Dividend yield	N/A
P/E ratio	0x

MRNA Stock Price Forecast for 2025 Based on Technical Analysis

Let’s conduct a technical analysis of MRNA shares on the weekly chart to determine price targets for the next 12 months.

Since mid-November 2024, the share price of US biotechnology company Moderna Inc. has been consolidating within a broad channel ranging from $18.00 to $48.90. At the moment, the asset price is trading at $32.16. Technical indicators and candlestick patterns suggest that the asset’s price will likely continue to increase:

• In the range of $36.72–$18.83, the price has formed a series of Hammer reversal candlestick patterns, which indicate an area of low prices and point to an imminent price reversal. Doji Gravestone candlestick patterns also indicate price reversals at the trend’s bottom, signaling a weakening of the bearish momentum.
• The MACD indicator values are gradually increasing in the positive zone, suggesting that bullish momentum is gaining traction.
• The MFI values are also rising, signaling an inflow of liquidity into the asset and an increase in demand from market participants.
• The RSI is moving in the neutral zone, holding at 47 and giving no clear buy or sell signals.
• The VWAP indicator and the SMA20 line are below the market price, which also indicates bullish pressure and the likelihood of the price breaking through the upper boundary of the accumulation channel.

The table below shows a forecast for Moderna (#MRNA) shares for the next 12 months.

Month	Minimum, $	Maximum, $
July 2025	23.30	37.61
August 2025	21.51	34.48
September 2025	32.69	54.60
October 2025	46.56	64.89
November 2025	42.08	51.03
December 2025	49.69	72.04
January 2026	68.91	88.59
February 2026	62.21	71.60
March 2026	59.08	77.86
April 2026	74.73	95.30
May 2026	97.09	114.97
June 2026	79.65	104.69

Long-Term Trading Plan for Moderna Inc. (#MRNA) for 2025

A technical analysis conducted on the weekly time frame has revealed key support and resistance levels for MRNA shares. These levels can be considered in trading strategies for the coming year.

Trading plan for 12 months

• The development of a bullish or bearish trend for the asset requires the price to break through the consolidation channel in which it currently resides.
• Key support levels: $22.23, $11.37, and $1.77.
• Key resistance levels: $42.68, $62.60, $84.23, $111.55, $134.32, and $164.49.
• The main long-term trading plan suggests that long positions can be opened above the key resistance level of $42.68 with targets in the $62.60–$134.32 range. The price is expected to hit the target within 12 months.
• An alternative long-term scenario implies opening short positions below the key support level of $22.23 with targets in the area of $11.37–$1.77.

Analysts’ MRNA Shares Price Projections for 2025

In the second half of 2025, Moderna shares may experience high volatility depending on the results of clinical trials of new vaccines, regulatory decisions, and broader market developments. Analysts predict a wide range of outlooks, from strong growth to a correction under pressure from competition and changing prospects for a potential pandemic.

LongForecast

Price range in 2025: $26.77–$46.28 (as of 18.07.2025).

LongForecast suggests that the value of MRNA shares may increase to $42.51 by the end of the third quarter. At the end of the year, analysts predict that the asset will likely reach $42.85.

Month	Open, $	Min–Max, $	Close, $
July	28.69	26.77–38.07	35.25
August	35.25	31.31–42.50	39.35
September	39.35	39.11–45.91	42.51
October	42.51	38.43–45.11	41.77
November	41.77	38.24–44.90	41.57
December	41.57	39.42–46.28	42.85

Gov Capital

Price range in 2025: $27.30–$43.51 (as of 18.07.2025).

According to Gov Capital, the value of Moderna shares may increase to $36.76 by October. By the end of 2025, analysts expect the rally to continue to $37.93.

Month	Minimum, $	Average, $	Maximum, $
July	29.12	32.35	35.59
August	28.30	31.45	34.59
September	27.30	30.33	33.36
October	33.09	36.76	40.44
November	35.59	39.55	43.51
December	34.14	37.93	41.73

CoinCodex

Price range in 2025: $29.97–$37.02 (as of 18.07.2025).

According to analysts from CoinCodex, the average price of the MRNA stock will reach $35.32 by the end of August. Notably, experts predict a bearish price reversal and a decline in quotes to around $31.12 between September and December.

Month	Minimum, $	Average, $	Maximum, $
July	31.58	34.13	37.02
August	34.44	35.32	36.83
September	32.30	34.43	36.67
October	29.97	32.45	33.60
November	30.04	31.59	33.77
December	30.47	31.12	31.97

Analysts’ MRNA Shares Price Projections for 2026

Due to the rapidly changing situation in the biotechnology industry, it is challenging to predict Moderna’s share price for 2026. However, analysts anticipate growth, which is expected to be driven by new developments in mRNA technology and the expansion of the vaccine portfolio. Optimistic scenarios indicate a substantial increase in Moderna’s share price.

LongForecast

Price range in 2026: $40.90–$76.24 (as of 18.07.2025).

LongForecast expects MRNA’s shares to stabilize at $42.85 in early 2026. By mid-year, analysts predict a steady increase in the average price to $50.67. In the second half of the year, the bullish trend will continue, and the price will likely reach $70.59 by the end of December.

Month	Open, $	Min–Max, $	Close, $
January	42.85	40.90–48.02	44.46
June	48.84	46.62–54.72	50.67
December	73.53	64.94–76.24	70.59

Gov Capital

Price range in 2026: $33.81–$66.32 (as of 18.07.2025).

According to investment portal Gov Capital, the price of MRNA could reach $37.57 at the beginning of 2026. Experts foresee an upward trend during the first half of the year. By mid-year, the price may surge to $60.29. In the second half of the year, prices are expected to reverse and stabilize at $45.91 by the end of December.

Month	Minimum, $	Average, $	Maximum, $
January	33.81	37.57	41.33
June	54.26	60.29	66.32
December	41.32	45.91	50.51

CoinCodex

Price range in 2026: $26.75–$30.71 (as of 18.07.2025).

CoinCodex anticipates the average value of Moderna to hover near $29.08 in early 2026. In the first half of the year, experts predict price fluctuations in the range of $26.75–$30.71, with an average price of $27.23 in June. In the second half of the year, the price may edge higher to $28.82.

Month	Minimum, $	Average, $	Maximum, $
January	27.73	29.08	30.71
June	26.75	27.23	27.57
December	28.36	28.82	29.36

Analysts’ MRNA Shares Price Projections for 2027

Forecasting Moderna’s share price by 2027 is difficult due to market volatility and the unpredictability of biotechnology developments. Optimistic scenarios predict growth thanks to the development of new vaccines and therapies. Pessimistic scenarios predict a decline due to competition and manufacturing constraints.

LongForecast

Price range in 2027: $60.02–$75.90 (as of 18.07.2025).

LongForecast predicts mixed performance for Moderna in 2027. At the beginning of the year, the price is expected to remain at $70.59. During the first half of the year, quotes will vary between $60.02 and $75.90, with an average price of $65.24 in June. By the end of the year, the price may recover to $70.26.

Month	Open, $	Min–Max, $	Close, $
January	70.59	64.66–75.90	70.28
June	66.04	60.02–70.46	65.24
December	70.60	64.64–75.88	70.26

Gov Capital

Price range in 2027: $26.64–$46.79 (as of 18.07.2025).

Gov Capital predicts that MRNA shares will increase to $41.03 by early 2027. The price will continue to grow until June, reaching $42.53, with a yearly high of $46.79. However, a bearish reversal is expected, with a decline to $29.60 by the end of December.

Month	Minimum, $	Average, $	Maximum, $
January	36.93	41.03	45.14
June	38.28	42.53	46.79
December	26.64	29.60	32.56

CoinCodex

Price range in 2027: $25.45–$29.12 (as of 18.07.2025).

Analysts from CoinCodex predict an average price of around $28.76 at the beginning of 2027. By midyear, prices are projected to drop to $26.90. During the latter half of the year, the downward trend may gain momentum, reaching approximately $25.67.

Month	Minimum, $	Average, $	Maximum, $
January	28.41	28.76	29.12
June	26.72	26.90	27.09
December	25.45	25.67	26.14

Analysts’ MRNA Shares Price Projections for 2028

It is challenging to forecast Moderna’s share price by 2028 due to the volatility of the biotechnology industry and the unpredictability of new drug development. However, given Moderna’s current market position, the potential for innovations in mRNA technology, and overall market trends, the stock could experience significant fluctuations.

LongForecast

Price range in 2028: $25.98–$70.26 (as of 18.07.2025).

According to the analytical portal LongForecast, the average price of MRNA shares at the beginning of 2028 may trade near $70.26. During the first half of the year, a significant drop in value is expected to $34.84 by the end of June. In the second half of the year, the bearish trend will continue, and the price may plummet to around $28.86.

Month	Open, $	Min–Max, $	Close, $
January	70.26	56.71–70.26	61.64
June	40.77	32.05–40.77	34.84
December	25.98	25.98–31.17	28.86

Gov Capital

Price range in 2028: $15.96–$28.40 (as of 18.07.2025).

Gov Capital predicts that the average price of the Moderna stock at the beginning of 2028 will be around $25.82. During the year, the price is expected to decline. Thus, by the end of the first half of the year, the asset may recover to $25.26, but by the end of the year, it may slide to $17.74.

Month	Minimum, $	Average, $	Maximum, $
January	23.24	25.82	28.40
June	22.73	25.26	27.78
December	15.96	17.74	19.51

CoinCodex

Price range in 2028: $24.31–$27.81 (as of 18.07.2025).

Analysts at CoinCodex predict that Moderna will trade at around $26.29 in early 2028. The first half of the year will see an upward trend, with the closing price reaching $27.40 in June. In the second half of the year, the price will decline, stabilizing at $24.40 by the end of December.

Month	Minimum, $	Average, $	Maximum, $
January	26.10	26.29	26.55
June	26.76	27.40	27.81
December	24.31	24.40	24.51

Analysts’ MRNA Shares Price Projections for 2029

Analysts predict moderate growth for Moderna shares in 2029, which may be driven by the expansion of its product portfolio to include new vaccines and mRNA-based therapeutics. The risks are related to competition and clinical trials.

Gov Capital

Price range in 2029: $17.93–$39.24 (as of 18.07.2025).

According to analysts at Gov Capital, the average price of MRNA shares at the beginning of 2029 will be around $19.93. By the end of the first half of the year, the asset value may increase to $21.36. In the second half of the year, experts anticipate growth to $35.67.

Month	Minimum, $	Average, $	Maximum, $
January	17.93	19.93	21.92
June	19.23	21.36	23.50
December	32.10	35.67	39.24

CoinCodex

Price range in 2029: $21.03–$28.74 (as of 18.07.2025).

CoinCodex offers a moderately negative outlook for MRNA shares in 2029. Thus, at the beginning of the year, the average price may reach $24.34. In the first half of the year, the quotes are likely to decline and reach $23.95 by the end of June. In the second half of the year, the bearish trend may accelerate to $23.56 in December.

Month	Minimum, $	Average, $	Maximum, $
January	24.17	24.34	24.53
June	23.91	23.95	23.99
December	21.03	23.56	28.74

StockScan

Price range in 2029: $196.30–$468.60 (as of 18.07.2025).

According to analysts at StockScan, the average value of Moderna securities will trade at $460.80 in early 2029. By the end of the first half of the year, the price may drop to $444.80. In the second half of the year, the downtrend is likely to intensify, and the price will plunge to $198.20 in December.

Month	Minimum, $	Average, $	Maximum, $
January	456.10	460.80	468.60
June	429.40	444.80	445.20
December	196.30	198.20	504.60

Analysts’ MRNA Shares Price Projections for 2030

Predicting Moderna’s share price by 2030 is challenging due to numerous unforeseen factors. However, given the potential of mRNA technology, the development of new vaccines and drugs, and the expansion of production, Moderna’s shares may appreciate substantially. However, fierce competition and regulation could have a negative impact.

CoinPriceForecast

Price range in 2030: $70.12–$82.68 (as of 18.07.2025).

According to CoinPriceForecast, the Moderna price may reach $70.12 in early 2030. In June, the upward trend will likely continue to $76.43, and by the end of the year, the asset may increase to $82.68.

Year	Mid-Year, $	Year-End, $
2030	76.43	82.68

CoinCodex

Price range in 2030: $10.37–$21.02 (as of 18.07.2025).

According to the investment portal CoinCodex, the average price of Moderna will trade around $16.61 in early 2030. By June, the value of MRNA shares is projected to decline to $11.74. However, experts predict a recovery to $16.32 by year-end.

Month	Minimum, $	Average, $	Maximum, $
January	13.18	16.61	21.02
June	10.37	11.74	12.72
December	14.99	16.32	17.87

StockScan

Price range in 2030: $197.30–$317.10 (as of 18.07.2025).

StockScan anticipates favorable prospects for Moderna in 2030. At the beginning of the year, the average share price may trade around $199.50. By midyear, the quotes are projected to surge to $244.50. In the second half of 2030, the bullish trend is expected to gain strength, with a projected price of $316.30 by the end of December.

Month	Minimum, $	Average, $	Maximum, $
January	197.30	199.50	202.70
June	235.70	244.50	244.60
December	297.50	316.30	317.10

Analysts’ MRNA Shares Price Projections until 2050

It is challenging to predict Moderna’s share price for the 2040–2050 period due to the uncertainty surrounding the impact of various fundamental factors on the price. These factors include technological breakthroughs, changes in the healthcare sector, competition, and global economic developments.

However, disregarding expert forecasts when formulating a long-term trading strategy would be a reckless decision. While they do not guarantee accuracy, such forecasts provide valuable guidance and allow you to assess potential risks and opportunities.

Experts at CoinPriceForecast are optimistic about the MRNA’s price until 2037. Analysts project that by 2035, the price will appreciate to $104.54, and by 2037, it will climb to $115.68.

Analysts from StockScan anticipate favorable long-term prospects for MRNA shares. According to analysts’ estimates, the stock may skyrocket to $1,116.00 by 2040 and to $1,474.00 by the end of 2050.

Year	CoinPriceForecast, $	StockScan, $
2035	104.54	804.20
2040	–	1,116.00
2045	–	1,293.00
2050	–	1,474.00

Forecasting Moderna’s share price for the 2040–2050 period is challenging due to the volatility associated with medical innovations, competitive forces, and regulatory shifts. However, the success or failure of the company’s current developments could have a significant impact on its value in the long term.

Market Sentiment for MRNA (Moderna) on Social Media

Media sentiment refers to the opinions of investors and traders that are shared through social media platforms. By analyzing this sentiment, we can assess the company’s appeal and investor confidence in Moderna shares. Positive sentiment often precedes a rise in share price, while negative sentiment can lead to a decline.

A user of social network X (formerly Twitter) with the username @lanemen notes the rise in MRNA shares amid positive results from phase 3 testing of a seasonal flu vaccine. This could have a positive impact on the company’s shares in the future.

User @DLSermersheim is convinced that mRNA vaccines will be successful against cancer and other diseases. The independent investor plans to buy MRNA shares if the company succeeds in this area.

A user with the nickname @iponzen notes that the investment company Investment Advisors has increased its stake by 167% by purchasing more than 21,000 shares. This indicates growing confidence on the part of institutional investors.

The sentiment of private investors and stock traders expressed in posts on social media platform X points to an optimistic outlook for Moderna shares.

#MRNA Price History

Moderna reached its all-time high of $484.47 on 09.08.2021. The lowest price of MRNA was recorded on 05.08.2019 when the stock declined to $12.26.

It is crucial to evaluate historical data to make our forecasts as accurate as possible. The chart below shows the #MRNA price performance over the last ten years.

Between January 2019 and December 2022, the Moderna stock exhibited high volatility and robust growth, mirroring the dynamic evolution of the biotechnology sector. The stock price began the year at $16.60 and saw a steady increase, reaching $20.35 by March 2019.

The pivotal moment occurred in 2020 amidst a global health crisis. Moderna’s contributions to the development of a coronavirus vaccine drove the stock price from $25.93 in February 2020 to a high of $173.16 in January 2021, showcasing an unparalleled surge. However, the peak was followed by fluctuations, with the stock price reaching a high of $497.49 in July 2021. After that, the stock began to slide, reaching a low of $179.62 in December 2022.

In 2023, MRNA’s stock price experienced a significant decline from $204.1 in January to a low of $65.27 in November. Nevertheless, the price has been on a gradual upward trajectory, reflecting a sustainable bullish trend.

However, this upward movement proved to be short-lived. Once the pandemic ended, demand for vaccines dropped, negatively impacting the company’s financial performance.

Since the beginning of 2025, MRNA shares have exhibited elevated volatility. In January, the price fluctuated between $31.94 and $48.90, driven by optimistic forecasts for the development of new vaccines. However, in February, the price dropped due to news of declining demand for COVID-19 vaccines. March and April were characterized by sideways movement until May, when there was a sharp jump associated with successful clinical trials of a new drug. A correction followed in June, and in the first two weeks of July, the price stabilized at $32.31, reflecting market uncertainty.

MRNA Shares Fundamental Analysis

Fundamental analysis involves evaluating a company’s performance based on its financial and operational metrics. In this section, we examine the key factors influencing Moderna’s share price, including economic conditions, technological innovation, and regulatory risks.

What Factors Affect the #MRNA Stock?

The MRNA share price movement depends on a variety of fundamental factors:

• Patents relating to mRNA technology. The COVID-19 pandemic challenged pharmaceutical companies, pushing their stocks higher with the development of coronavirus vaccines, but now the price is slowly declining.
• Regulatory changes. The regulatory landscape for healthcare companies can both increase and decrease research and manufacturing costs.
• Macroeconomic conditions. Inflation, interest rates, and geopolitical events affect MRNA stocks. During periods of economic uncertainty, investors often shift their priorities and turn to safe-haven assets to preserve their capital. Against this backdrop, stocks may see wide fluctuations.
• Consumer spending. In the absence of global risks of emerging infectious diseases, the development of new vaccines is greatly diminished. As a result, investors are reluctant to invest in expensive research.

More Facts About Moderna Inc. (#MRNA)

Moderna, Inc. is one of the largest biotechnology companies in the United States, specializing in the development of messenger RNA-based drugs. The company was founded in 2010.

During the COVID-19 pandemic, Moderna, Inc. was developing a coronavirus vaccine, which caused its stock price to rise significantly. In addition, MRNA was included in the S&P 500 Index on July 21, 2021, replacing the pharmaceutical company Alexion Pharmaceuticals. These two factors attracted investors to Moderna, Inc., but it was a short-lived interest.

Advantages and Disadvantages of Investing in #MRNA

Investing in MRNA shares has its advantages and disadvantages, which are important to consider when making decisions.

Advantages

• Moderna is actively developing mRNA-based vaccines for cancer and cardiovascular disease treatment.
• The company is included in the S&P 500 index, reflecting its market significance and institutional investor confidence.
• Moderna has strong strategic partnerships, including collaborations with UNICEF and governments in low-income countries.
• The company invests in AI technologies to accelerate drug discovery and development.
• Moderna has expertise in large-scale production and distribution of biologics.

Disadvantages

• Lower demand for drugs may weaken financial performance and put pressure on MRNA’s value.
• Intense competition in the biotechnology sector, with strong players like Pfizer and BioNTech potentially limiting market share.
• High risk of clinical trial failures.
• The lack of a diverse portfolio of commercially successful products increases business vulnerability.
• The stock remains highly volatile and prone to sharp swings, even in response to relatively minor news.

Remember that investing in the biotechnology sector always involves a high degree of uncertainty. Despite Moderna’s scientific potential, the stock remains volatile. Therefore, investors should weigh all risks before making decisions.

How We Make Forecasts

We employ a comprehensive methodology to build forecasts:

• Short-term forecasts are based on market data. Technical analysis and indicators help to identify the current trend on lower time frames.
• Medium-term forecasts rely on fundamental analysis involving the assessment of earnings, the debt-to-equity ratio, dividends, reputation, innovative technologies, etc.
• Long-term forecasts take into account behavioral patterns specific to the industry, broader market trends, the company’s position within its sector, and projections from independent analysts.

In order to make an accurate and comprehensive forecast, we consider both internal factors affecting the price of an asset and external factors.

Conclusion: Is MRNA a Good Investment?

Investing in Moderna shares is a promising but risky opportunity. The success of the vaccines developed to combat COVID-19 has demonstrated the potential of a new method of vaccine development based on the use of mRNA for the treatment of various diseases. However, despite its promising prospects, mRNA technology is still in its early stages of development, and the future profitability of companies specializing in mRNA remains uncertain.

Prior to making an investment decision, it is crucial for investors to thoroughly assess the risks and potential prospects, diversify their portfolios, and conduct comprehensive analyses.

Price chart of MRNA in real time mode